| Subject: | FDA Warns of Counterfeit Alli 60 mg Capsules |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 18 Jan 2010 - 04:00 pm |
| Audience: Consumers, Pharmacy healthcare professionals The Food and Drug Administration (FDA) has notified consumers and healthcare professionals about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). The counterfeit version contains the controlled substance sibutramine and does not contain orlistat, the correct active ingredient for this product. Sibutramine is a drug that should not be used in certain patient populations or without physician... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
